Jinhe Biotechnology(SZ:002688)2022-12-06 08:52Group 1: Market Demand and Growth Drivers - The main drivers for the growth of the feed-grade gold mycin industry include an increase in breeding volume, higher per-animal usage, and rising prices. The domestic market has significant long-term growth potential due to intensified farming practices and improved awareness of medication among farmers [2][3]. - The expansion into emerging foreign markets is expected to create substantial demand growth for gold mycin [3]. Group 2: Company Developments and Strategic Positioning - After acquiring Panfield, the subsidiary Pharmaway has shifted its focus to directly producing and selling animal health products in the U.S. market, including gold mycin and other feed additives [3]. - The company successfully completed a non-public stock issuance in February 2016, with future financing activities to be determined based on strategic planning and development [4]. Group 3: Future Plans and Environmental Initiatives - The company aims to become a world-leading animal health product enterprise, enhancing its competitive edge in biopharmaceuticals and feed additives while actively developing new products and expanding its market influence [4]. - The subsidiary Inner Mongolia Jinhe Environmental Technology Co., Ltd. focuses on high-concentration industrial wastewater treatment, currently processing 10,000 tons of wastewater daily, with plans for nationwide business expansion [5]. Group 4: Acquisitions and Product Diversification - The acquisition of a 67% stake in Hangzhou Jianliang Veterinary Biological Products Co., Ltd. is significant due to the stringent regulatory environment for veterinary biological products, allowing the company to quickly enter the vaccine sector and diversify its product offerings [6].